Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

Core Insights - Prelude Therapeutics announced the acceptance of a poster presentation for its oral KAT6A selective degrader (PRT13722) at the AACR Annual Meeting 2026, scheduled for April 17-22 [1] - The company aims to file an IND in mid-2026 and initiate clinical trials in the second half of 2026 for PRT13722, which is expected to improve efficacy and tolerability in treating ER+ breast cancer [2][4] Presentation Details - The poster titled "First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile" will be presented on April 21, 2026, from 2:00 PM to 5:00 PM [3] - The presentation will be part of the Experimental and Molecular Therapeutics session, located at Poster Section 15, Board Number 20, Poster Number 5793 [3] Product Development - Prelude is developing a highly selective KAT6A oral degrader, which is believed to offer improved efficacy and tolerability compared to non-selective inhibitors [4] - The company has previously presented initial preclinical data supporting the potential of KAT6A as a target for ER+ breast cancer at the AACR Annual Meeting 2025 [5] Educational Session - On April 18, 2026, Prelude's Director of Biology and Translational Research will present a lecture on "Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes with Targeted Protein Degrader-Antibody Conjugates (DACs)" during an educational session [6] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, including KAT6A degraders and JAK2V617F mutant selective inhibitors, targeting areas of high unmet need in cancer treatment [6]